USA – Codagenix, a Farmingdale, New York-based clinical-stage synthetic biology company, raised $25M in Series B Extension funding.
The round was led by Serum Institute of India with participation from existing investors Euclidean Capital and Adjuvant Capital.Led by CEO J. Robert Coleman, Codagenix is a clinical-stage biotechnology company which specializes in live vaccines and viral therapeutics. Its platform brings together live-attenuated virus design with codon deoptimization for synthetic biology-based solutions to take on threats in infectious disease, cancer and animal health. The company intends to use the funds for the clinical development of CodaVax-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) disease. The funding will also support additional cohorts in an ongoing Phase 1 study for CodaVax-H1N1, a universal, live-attenuated influenza vaccine in 1H23 and expansion of its oncology program.Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University. 15/02/2023
